Healthy Living/WellnessEli Lilly's Jardiance Diabetes Treatment Steals Market Share From Rival Drugs Eli Lilly's new diabetes treatment Jardiance stole market share from its rivals. The increased market share of 25 percent of new U.S. patients was attributed to clinical trial data showing fewer deaths among type 2 diabetics by 32 percent.by Katrina Pascual
Healthy Living/WellnessJohnson & Johnson Advanced Multiple Myeloma Drug Darzalex Wins Accelerated FDA Approvalby Katherine Derla
Healthy Living/WellnessRevolutionary HIV Treatment Could Be Underway As Clinical Trial Shows Promising Result For Combination Drugby Katherine Derla
Healthy Living/WellnessJohnson & Johnson Starts Clinical Trial Of Ebola Vaccine In Sierra Leoneby Rhodi Lee
Healthy Living/WellnessJohnson & Johnson Calls On Ethicists To Weigh In On Drug Trialsby Dianne Depra
Healthy Living/WellnessIBM Establishes Watson Health Cloud With Apple, J&J, And Medtronicby Dianne Depra
Healthy Living/WellnessBoston Scientific, Johnson & Johnson Bury The Hatchet With $600 Million Settlementby Dianne Depra
Healthy Living/WellnessJohnson & Johnson halts sale of power morcellators for fibroid surgeryby Rhodi Lee
Healthy Living/WellnessFDA shows no love for Johnson & Johnson Xarelto blood thinner, rejects expanded use for 3rd timeby Randell Suba